Axiom ANALYTICS

CERTIFICATE OF ANALYSIS · 4X ESSENTIAL PANEL + 1 ADD-ON LAYER (L8)

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4500-AKD9

CJC / Ipamorelin Blend 10 mg · Lot L-CJC-05
Issued Oct 15, 2026 PT · v1
Verify: 9B06-E5BE-2AFC


SCAN TO VERIFY

PASS — ALL SPECIFICATIONS MET

5 of 5 layers complete

L1	L2	L3	L4	L8
Identity	Purity	Net Peptide Content	Sterility	Fentanyl Screen

Sample & Vial Validation



Vial A: as received & analyzed

MORE VIEWS OF VIAL A



Vial A · right

Brand	**Research Vault Group**	Product	**CJC / Ipamorelin Blend 10 mg**
Lot / Batch	**L-CJC-05**	Label Claim	**CJC 5 mg / Ipamorelin 5 mg**
Matrix	**Lyophilized powder**	Sample Count	**1**
Vial Size	**3mL**	Cap Color	**Translucent Blue**
Crimp Color	**Silver / Aluminum**	Contents Color	**White**
Seal Intact	**Yes**	Condition	**sealed, intact**
Received	**Oct 9, 2026 PT**	Sampling	**client submitted**

Test Results

Test	Specification	Result	
Identity research screen	every declared component within ±1 Da of its own theoretical mass	`2 of 2 components confirmed`	PASS
Purity research screen	each declared component at or above its own locked purity criterion	`99.48%`	PASS
Net Peptide Content research screen	each declared component within its own locked content criterion, at the declared ratio	`10.42 mg`	PASS
Sterility · Rapid PCR research screen	Rapid PCR screen	`Target DNA not detected`	PASS
Fentanyl Screen research screen	no fentanyl or analog at or above 1 ng/mg	`none detected`	PASS

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4500-AKD9

CJC / Ipamorelin Blend 10 mg · Lot L-CJC-05
Issued Oct 15, 2026 PT · v1
Verify: 9B06-E5BE-2AFC

SCAN TO VERIFY

Layer Results

1 Identity

LC-MS (ESI+)

2 of 2 components confirmed
every declared component within ±1 Da of its own theoretical mass

PASS

Component	Its criterion	Observed	Status
CJC-1295 no DAC	3367.954 Da · acceptance ±1 Da · average	3367.807 Da	PASS Recorded component call: PASS Calculated comparison: within criterion Signed layer call: PASS
Ipamorelin	711.868 Da · acceptance ±1 Da · average	711.875 Da	PASS Recorded component call: PASS Calculated comparison: within criterion Signed layer call: PASS


Theoretical mass **3367.954 Da** Acceptance **within ±1 Da**

Vial A **2 of 2 components confirmed**

Component	Theoretical	Observed	Mass error	Identity
CJC-1295 no DAC	3367.954 Da	3367.807 Da	-0.147 Da (-43.6 ppm)	CONFIRMED
Ipamorelin	711.868 Da	711.875 Da	+0.007 Da (9.8 ppm)	CONFIRMED



CJC-1295 no DAC accurate mass against its identity tolerance: 3367.954 Da ± 1 Da (average)



Ipamorelin accurate mass against its identity tolerance: 711.868 Da ± 1 Da (average)

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4500-AKD9

CJC / Ipamorelin Blend 10 mg · Lot L-CJC-05
Issued Oct 15, 2026 PT · v1
Verify: 9B06-E5BE-2AFC

SCAN TO VERIFY

2 Purity

RP-HPLC 214nm (USP 621)

99.48% each declared component at or above its own locked purity criterion — PASS

Component	Its criterion	Observed	Status
CJC-1295 no DAC	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.42%	PASS Recorded component call: not recorded Calculated comparison: within criterion Signed layer call: PASS
Ipamorelin	Expected Purity ≥ 99.25 area % · Acceptance NLT 99.25 area % · Units area % · Source Axiom Analytics SPEC-PURITY-001, Revision 1, effective 2026-08-31	99.53%	PASS Recorded component call: not recorded Calculated comparison: within criterion Signed layer call: PASS

Acceptance **Each component NLT 99.25 area %** Vial A **99.48% · PASS**



CJC-1295 no DAC purity against its criterion: NLT 99.25 area %



Ipamorelin purity against its criterion: NLT 99.25 area %

3 Net Peptide Content

Quantitative HPLC vs reference std

10.42 mg each declared component within its own locked content criterion, at the declared ratio — PASS

Component	Its criterion	Observed	Status
CJC-1295 no DAC	1 part · 4.5–5.5 mg · Declared blend recipe on the controlled Axiom catalog record for CJC-1295 (No DAC)/Ipamorelin (component ratio 1); acceptance ±10% per Axiom SPEC-CONTENT-001	5.22 mg	PASS Recorded component call: not recorded Calculated comparison: within criterion Signed layer call: PASS
Ipamorelin	1 part · 4.5–5.5 mg · Declared blend recipe on the controlled Axiom catalog record for CJC-1295 (No DAC)/Ipamorelin (component ratio 1); acceptance ±10% per Axiom SPEC-CONTENT-001	5.2 mg	PASS Recorded component call: not recorded Calculated comparison: within criterion Signed layer call: PASS

Observed ratio **CJC-1295 no DAC 1.00 : Ipamorelin 1.00** against declared **CJC-1295 no DAC 1.00 : Ipamorelin 1.00** · source Declared blend recipe on the controlled Axiom catalog record for CJC-1295 (No DAC)/Ipamorelin (component ratio 1); acceptance ±10% per Axiom SPEC-CONTENT-001

Target **10 mg (±10%)** Confirmed container volume **Unknown**

Content concentration **Unknown**

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

Axiom Analytics Laboratories
2108 N St Ste N, Sacramento, CA 95816 US

AX-2026-4500-AKD9

CJC / Ipamorelin Blend 10 mg · Lot L-CJC-05
Issued Oct 15, 2026 PT · v1
Verify: 9B06-E5BE-2AFC

SCAN TO VERIFY

4 Sterility · Rapid PCR

Rapid Microbial DNA Screen (qPCR target panel)

Target DNA not detected — Rapid PCR screen — PASS

Result	**Target DNA not detected**	Acceptance	**Rapid PCR screen**
Target panel	**Pan-bacterial 16S rRNA gene (VIC), Pan-fungal 18S rRNA gene (FAM)**		

Run controls valid.

8 Fentanyl Screen

LC-MS/MS targeted adulterant screen

none detected — no fentanyl or analog at or above 1 ng/mg — PASS

Result	**Not detected**	Detection limit	**1 ng/mg**
Analytes screened	**Fentanyl, Acetylfentanyl, Acrylfentanyl, Butyrylfentanyl, Carfentanil, Cyclopropylfentanyl, Furanylfentanyl, Methoxyacetylfentanyl, ortho-Fluorofentanyl, Valerylfentanyl, 4-ANPP (despropionyl fentanyl)**	Source container	**A**

Reporting Scope & Limitations

`[Sterility · Rapid PCR]` DNA-target research screen only. It detects microbial DNA from viable and non-viable organisms alike, and is neither viable-CFU enumeration under USP <61> nor a batch sterility determination under USP <71>.

`[Fentanyl Screen]` Targeted LC-MS/MS adulterant screen, reported as detected or not detected against its stated detection limit. A harm-reduction research screen, not an exhaustive adulterant panel.

Digital Signatures

Analyst	**Alana Reeves**	Analyst Signature	**ed25519:d48e67b6a5c4cce90c9a51a9...**
Technical Reviewer	**Michael Niles**	Reviewer Signature	**ed25519:d273bf013fca115b7613dc63...**
Laboratory Director	**Daniel Brennan**	Director Signature	**ed25519:c26eb91a83d4c9de99e8e482...**

Where physical instrument analysis is performed, it takes place within Axiom Analytics' laboratory network, allocated at Axiom's discretion based on method, capacity, and order volume. Axiom Analytics performs sample accession, chain of custody, analytical oversight, and data review, and issues and is responsible for this certificate. Where analysis is subcontracted, the method is performed within the partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory holding ISO/IEC 17025 accreditation. Axiom Analytics does not itself currently hold ISO/IEC 17025 accreditation. The method-validation status of each reported result is identified beside that result. Partner laboratory identities are not disclosed: where samples are analyzed under double-blind conditions, they are identified only by an internal lot ID.

Each signature is an ed25519 signature over the SHA-384 hash of this report. Scan the QR on the letterhead or verify independently at https://axiomanalyticslab.com/verify/AX-2026-4500-AKD9.

✓ CRYPTOGRAPHICALLY SEALED (ed25519 + SHA-384)

SHA-384: 9b783d9937530635db185e8d284692c34e76e34216ec0f509a7cf3c5224dd750...

Seal: ed25519:8b87fd86ade2643759dcf9fc03a126476f44204c...

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.

RESEARCH USE ONLY. All analytical testing, validation reports, and interactive Certificates of Analysis (COAs) provided by Axiom Analytics are intended strictly for Research Use Only (RUO) in in-vitro or laboratory animal model environments. Axiom Analytics does not analyze, validate, evaluate, or make any representations regarding the safety, efficacy, toxicity, or legality of any tested substance for human or animal consumption, veterinary use, clinical diagnostics, food additives, cosmetics, or household applications.

Results relate only to the item or portion tested. Unless sampling was performed or witnessed by Axiom Analytics, the laboratory does not attest that the submitted sample represents the wider lot or batch. A PASS designation means only that the reported result met the specification shown. It does not establish safety, efficacy, regulatory approval, legality, or suitability for human or animal use.